Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500mg/dl ... name CARVYKTI ® for the treatment of adults with relapsed or refractory multiple myeloma. In April 2024, ...

Further analysis revealed that felzartamab administration resulted in selective and durable reductions in IgA antibody levels, while IgG and IgM levels recovered ... developed by MorphoSys AG for ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

The department used its new system for determining whether a condition is service-connected to give affected veterans access ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...